Standard InChI: InChI=1S/C32H31NO6/c1-37-27-19-25(20-28(21-27)38-2)31(34)33(18-8-11-23-9-4-3-5-10-23)22-24-14-16-26(17-15-24)39-30-13-7-6-12-29(30)32(35)36/h3-7,9-10,12-17,19-21H,8,11,18,22H2,1-2H3,(H,35,36)
1.Beck HP, Kohn T, Rubenstein S, Hedberg C, Schwandner R, Hasslinger K, Dai K, Li C, Liang L, Wesche H, Frank B, An S, Wickramasinghe D, Jaen J, Medina J, Hungate R, Shen W.. (2008) Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents., 18 (3):[PMID:18178086][10.1016/j.bmcl.2007.12.024]
2.Terakado M, Suzuki H, Hashimura K, Tanaka M, Ueda H, Kohno H, Fujimoto T, Saga H, Nakade S, Habashita H, Takaoka Y, Seko T.. (2016) Discovery of ONO-7300243 from a Novel Class of Lysophosphatidic Acid Receptor 1 Antagonists: From Hit to Lead., 7 (10):[PMID:27774128][10.1021/acsmedchemlett.6b00225]
3.Meduri B, Pujar GV, Durai Ananda Kumar T, Akshatha HS, Sethu AK, Singh M, Kanagarla A, Mathew B.. (2021) Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development., 222 [PMID:34126459][10.1016/j.ejmech.2021.113574]